Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxo...
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
About this item
Full title
Author / Creator
Publisher
Poland: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Poland: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Cisplatin, mitomycin C and anthracyclines demonstrate high activity in BRCA1-deficient tumors. This study aimed to evaluate the efficacy of the triplet combination of these drugs in BRCA1-driven high-grade serous ovarian carcinomas (HGSOCs).
Ten HGSOC patients with germ-line BRCA1 mutation received neoadjuvant chemotherapy (NACT) consisting of m...
Alternative Titles
Full title
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e6bae727d3b348d2a15b6c1b9e0e6d04
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e6bae727d3b348d2a15b6c1b9e0e6d04
Other Identifiers
ISSN
1897-4287,1731-2302
E-ISSN
1897-4287
DOI
10.1186/s13053-021-00173-2
